SCHEMBL7100482

SCHEMBL7100482

CCCCC(Br)CS(=O)(=O)O.[NaH]

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
LCK P06239 1/20 0.35
PPARD Q03181 1/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35
RECQL P46063 1/20 0.35
FDPS P14324 1/20 0.34
CA2 P00918 4/20 0.33
MAPK1 P28482 1/20 0.33
GPR84 Q9NQS5 3/20 0.32
CA1 P00915 2/20 0.32
ZDHHC7 Q9NXF8 1/20 0.32
FFAR1 O14842 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SLC22A6 Q4U2R8 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28655800 0.98 TP53 (0.41) TP53LCKPPARDZDHHC20ZDHHC2
SCHEMBL28327731 0.96 TP53 (0.39) TP53LCKPPARDZDHHC20ZDHHC2
SCHEMBL9392661 0.81 TP53 (0.41) TP53FDPSCA2MAPK1GPR84
SCHEMBL1138500 0.78 TP53 (0.42) TP53FDPSCA2MAPK1GPR84
SCHEMBL7103231 0.77 TP53 (0.32) TP53LCKPPARDZDHHC20ZDHHC2
SCHEMBL31544523 0.76 ALDH1A1 (0.44) TP53RECQLFDPSCA2MAPK1
SCHEMBL7100480 0.75 CA2 (0.35) TP53LCKPPARDZDHHC20ZDHHC2
SCHEMBL125029 0.75 ALDH1A1 (0.50) TP53RECQLCA2MAPK1CA1
SCHEMBL10923556 0.75 TP53 (0.35) TP53LCKPPARDZDHHC20ZDHHC2
SCHEMBL15754300 0.75 TP53 (0.48) TP53FDPSGPR84FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020443-B1 PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF AZWELL INC (JP) 2003-09-10 EP disclosed
US-6572839-B2 Xanthene dye structure with a hydrophilic and lipophilic group bound to the same carbon, ultrasonic HITACHI, LTD. (JP) 2003-06-03 US disclosed
US-20010041163-A1 Sensitizer for tumor treatment HITACHI, LTD. (JP) 2001-11-15 US disclosed
US-6172228-B1 Process for producing piperazinesulfonamide derivatives and salts thereof AZWELL INC. (JP) 2001-01-09 US disclosed
EP-1020443-A1 PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF Azwell Inc. (JP) 2000-07-19 EP disclosed
EP-1020437-A1 PROCESS FOR PRODUCING HALOGENOALKYLSULFONAMIDE DERIVATIVES Azwell Inc. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041163-A1 Sensitizer for tumor treatment HNRNPR, HNRNPUL1, SON TP53 12/4885LCK 4714/4885PPARD 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.